Windtree Therapeutics (WINT) AI Stock Analysis

• Market Cap: $674.18K
• Dividend Yield: N/A
• Average Volume (3M): 403.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: N/A
• EPS Growth: 99.09%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.08
• Shares Outstanding: 33,708,782
• 10 Day Avg. Volume: 496,404
• 30 Day Avg. Volume: 403,289
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.06
• Enterprise Value/Market Cap: 20.99
• Enterprise Value/Revenue: 157.25
• Enterprise Value/Gross Profit: 1.29K
• Enterprise Value/Ebitda: -1.20
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $0.02 ▼(-36.67% Downside)

The score is driven primarily by very weak financial fundamentals (minimal revenue, large losses, heavy cash burn, and negative equity with rising debt) and a strongly bearish technical picture (price below all key moving averages with negative MACD and very weak RSI/Stoch). Valuation provides little support due to losses and no dividend, while the abrupt senior leadership departure adds incremental risk.

Positive Factors

Focused Therapeutic Pipeline

A targeted R&D focus on severe acute and cardiopulmonary illnesses addresses high unmet medical need and supports long-term value if clinical progress continues. Specialized programs can command premium pricing and partner interest, making the business model strategically coherent.

Access to External Capital

The company has demonstrated the ability to secure external financing via convertible notes to fund strategic moves. Continued access to capital markets is critical for small biotechs to sustain R&D and acquisitions over the coming months, supporting program continuity.

Lean Cost Structure

A small employee base implies a lean operating model with lower fixed overhead, which can extend runway and enable flexible outsourcing of R&D and development functions. This structure helps preserve cash while pursuing pivotal clinical or partnership milestones.

Negative Factors

Balance Sheet Deterioration

Negative equity combined with rising debt signals materially weakened financial resilience. Extreme leverage versus equity limits strategic optionality, raises refinancing risk, and increases the likelihood of dilutive recapitalizations that can constrain long-term shareholder value.

Persistent Cash Burn

Sustained negative operating and free cash flow of roughly -$15.1M TTM reflects structural funding needs. Persistent cash burn forces reliance on external financing, heightens dilution or debt risk, and can interrupt R&D programs if new capital is delayed or costly.

Executive Turnover Risk

The abrupt departure of a senior executive creates short- to medium-term execution risk for strategy, fundraising, and program oversight. Leadership instability can delay decision-making, complicate investor relations, and make sustaining partnerships or regulatory progress harder.

Windtree Therapeutics Business Overview & Revenue Model

Company Description

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

How the Company Makes Money

Windtree Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products, including licensing agreements and collaboration partnerships. The company may receive milestone payments, royalties, and other financial support from partnerships with larger pharmaceutical companies interested in their novel therapies. Additionally, Windtree may secure funding through government grants or research and development contracts aimed at advancing its clinical trials and product development initiatives. The company's financial success is closely tied to the progress and approval of its drug candidates in regulatory pathways and the subsequent commercialization efforts.

Windtree Therapeutics Financial Statement Overview

Summary

Windtree Therapeutics is in a challenging financial situation, with no revenue generation and significant net losses impacting its financial health. The balance sheet shows a leveraged position with declining equity, while cash flows indicate reliance on external financing. The lack of revenue severely limits potential growth opportunities and stability in the biotechnology sector.

Income Statement

The company has reported zero revenue over the years, leading to negative profitability metrics. Consistent net losses highlight significant operational challenges, with no revenue growth potential in sight. The lack of revenue and high net losses severely impact the overall financial health.

Balance Sheet

The company shows a weak financial position with declining stockholders' equity over the years. The debt-to-equity ratio is relatively high, indicating significant leverage, though the current debt levels are not excessively high. The company needs to improve its equity base to stabilize its balance sheet.

Cash Flow

The cash flow position is strained with consistently negative operating and free cash flows, indicating insufficient cash generation from operations. Financing activities have been a key source of cash, highlighting reliance on external funding. The company faces challenges in maintaining cash reserves without revenue generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	90.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	11.00K	-84.00K	-82.00K	-1.06M	-869.00K	-638.00K
EBITDA	-11.77M	-1.47M	-20.16M	-39.46M	-76.64M	-31.80M
Net Income	-40.86M	-5.49M	-20.29M	-39.21M	-67.64M	-30.28M
Balance Sheet
Total Assets	15.98M	27.88M	32.41M	37.95M	74.79M	112.89M
Cash, Cash Equivalents and Short-Term Investments	204.00K	1.78M	4.32M	6.17M	22.35M	16.93M
Total Debt	12.93M	1.82M	16.83M	2.28M	2.89M	3.78M
Total Liabilities	27.58M	17.88M	29.02M	27.94M	32.91M	43.33M
Stockholders Equity	-11.61M	10.00M	3.39M	10.01M	41.88M	69.55M
Cash Flow
Free Cash Flow	-15.12M	-15.41M	-13.45M	-19.46M	-23.94M	-25.61M
Operating Cash Flow	-15.12M	-15.40M	-13.44M	-19.45M	-23.66M	-25.32M
Investing Cash Flow	-5.97M	-12.00K	-15.00K	197.00K	-279.00K	-291.00K
Financing Cash Flow	19.00M	12.73M	11.60M	3.08M	29.36M	19.96M

Windtree Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WINT, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.05, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 17.84 is Positive, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WINT.

Windtree Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDP	46 Neutral	$6.55M	-0.11	-317.98%	―	―	34.57%
TOVX	45 Neutral	$7.39M	-0.04	-166.96%	―	―	83.25%
AZTR	45 Neutral	$3.70M	-0.06	-215.04%	―	-100.00%	93.82%
ENVB	42 Neutral	$4.18M	-0.04	-262.78%	―	―	79.45%
ARTL	41 Neutral	$3.35M	-0.08	-436.14%	―	―	-22.52%
WINT	39 Underperform	$674.18K	>-0.01	―	―	―	99.09%

Windtree Therapeutics Corporate Events

Windtree Therapeutics Announces Sudden Departure of President and COO

On January 5, 2026, Windtree Therapeutics, Inc. announced that Eric L. Curtis resigned from his roles as President and Chief Operating Officer, effective immediately. The abrupt leadership change may signal a period of transition for the company’s executive team and could prompt investors and other stakeholders to reassess management stability and future strategic direction.

The most recent analyst rating on (WINT) stock is a Hold with a $0.03 price target. To see the full list of analyst forecasts on Windtree Therapeutics stock, see the WINT Stock Forecast page.

Windtree Therapeutics Issues Convertible Notes for Acquisition

On November 25, 2025, Windtree Therapeutics issued $857,142.86 in senior convertible promissory notes due 2026 to fund the acquisition of CommLoan Inc. and for corporate purposes. The notes, which mature in 2026, include provisions for conversion into common stock, prepayment conditions, and adjustments in case of equity financing, impacting the company’s financial strategy and stakeholder interests.

Windtree Therapeutics Issues Convertible Notes for Settlement

On October 9, 2025, Windtree Therapeutics issued $1.6 million in senior convertible promissory notes to institutional investors. This move was part of a settlement related to a previous real estate agreement and positions the company to manage its financial obligations while potentially benefiting from future equity financing. The notes, due in 2026, carry a 10% annual interest and include provisions for conversion into common stock, reflecting strategic financial maneuvering to bolster the company’s capital structure.